Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech, Inc. (Nasdaq: ONCY) is a clinical-stage biotechnology company whose news flow centers on the development of pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Company updates frequently highlight clinical data in metastatic pancreatic cancer, metastatic breast cancer, and gastrointestinal tumors such as anal and colorectal cancers, where pelareorep is being evaluated in combination with chemotherapy and checkpoint inhibitors.
News releases from Oncolytics often cover clinical trial milestones, including results from the GOBLET study in squamous cell anal carcinoma and colorectal cancer, as well as alignment with the U.S. Food and Drug Administration on pivotal trial designs in first-line metastatic pancreatic ductal adenocarcinoma. Investors can also expect announcements about planned registration-directed studies, accelerated approval strategies in indications with no FDA-approved therapies, and translational findings such as tumor-specific T-cell responses in KRAS-mutant metastatic colorectal cancer.
Oncolytics’ news also addresses corporate and regulatory developments, including its proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada, its transition to domestic issuer status under SEC rules, and capital markets activities such as at-the-market equity programs. Additional updates describe expansions of the company’s Gastrointestinal Tumor Scientific Advisory Board and appointments of senior leaders in strategy, operations, and biostatistics to support late-stage clinical execution.
This ONCY news page aggregates these press releases and related coverage so readers can follow key developments in pelareorep’s clinical progress, regulatory interactions, intellectual property initiatives, and corporate strategy. It is a useful resource for tracking how new data, advisory board input, and structural changes may influence the company’s oncology pipeline over time.
Oncolytics Biotech has initiated the IRENE study, a phase 2 trial examining the combination of pelareorep and Incyte's anti-PD-1 checkpoint inhibitor, retifanlimab, in treating unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The first patient has been dosed as part of this multi-center study, co-sponsored with Rutgers Cancer Institute and The Ohio State University. The trial aims to assess safety, efficacy, PD-L1 expression changes, and T cell clonality. This innovative approach addresses the urgent need for effective treatments in the aggressive TNBC subtype.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced its participation in the virtual Canaccord Genuity 40th Annual Growth Conference on August 12, 2020. CFO Kirk Look will present at 8:00 am ET, with a live webcast available here. The Company will also conduct one-on-one investor meetings. Oncolytics is focused on developing pelareorep, an immuno-oncolytic virus for cancer treatment, which shows promise in combination with other therapies. For further updates, visit the Company's website.
Oncolytics Biotech reported its Q2 2020 financial results, highlighting significant clinical progress despite COVID-19 challenges. The company initiated the BRACELET-1 trial and presented promising data at the ESMO meeting, confirming the mechanism of action for its lead product, pelareorep. Financially, Oncolytics had $29.9 million in cash but recorded a net loss of $6.8 million, with a diluted loss per share of $0.17. The firm also established an ATM facility to bolster financial flexibility for ongoing clinical trials.
Oncolytics Biotech (NASDAQ: ONCY) announced a conference call on August 4, 2020, at 4:30 PM ET to discuss its second-quarter financial results. The company is focused on its clinical candidate, pelareorep, which is designed to treat various cancers by inducing tumor lysis and enhancing immune responses. Oncolytics is currently preparing for a phase 3 registration study in metastatic breast cancer. Potential risks include interruptions from COVID-19 affecting operations and clinical trials.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced a new phase 2 study, IRENE, to investigate the combination of pelareorep and Incyte's retifanlimab in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Conducted by Rutgers Cancer Institute and Ohio State University, the study aims to evaluate safety, objective response rate, and changes in PD-L1 expression in 25 patients. This trial represents an expansion of Oncolytics' breast cancer program and may pave the way for enhanced treatment options in a challenging indication.
Oncolytics Biotech announced the first patient dosing in the phase 2 BRACELET-1 study for HR+/HER2- metastatic breast cancer, under a co-development agreement with Merck KGaA and Pfizer. The study evaluates combination therapies with pelareorep and aims to validate T cell clonality as a biomarker for treatment response. The prior phase 2 trial showed promising results, indicating a near doubling of overall survival. The study will involve 45 patients and will assess safety, tolerability, and efficacy, with results potentially impacting future cancer treatment protocols.
Oncolytics Biotech has initiated an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity, enabling it to raise up to $40 million over 25 months. The ATM provides flexibility to sell common shares at market prices, enhancing the company’s financial positioning for ongoing development and clinical trials of its immuno-oncolytic virus, pelareorep. This strategy may strengthen Oncolytics’ capacity to negotiate future business agreements. The prospectus for this offering has been filed with the appropriate securities commissions.